How new pancreatic cancer pill doubles survival rate, Pg18

Key Highlights:

• A new experimental oral drug, daraxonrasib, has shown promise for patients with advanced pancreatic cancer.
• Clinical trial results indicate it nearly doubles survival time in patients whose disease progressed after prior treatment.
• The drug specifically targets the KRAS gene mutation, a primary driver in approximately 80% of pancreatic cancers.
• This breakthrough was presented at an American Society of Clinical Oncology meet.
• It marks a significant advancement in the field of precision oncology for a historically difficult-to-treat cancer.

Detailed Insights:

• Pancreatic cancer is notoriously difficult to treat, with 70-90% of patients diagnosed at an advanced stage.
• Historically, the median survival for advanced pancreatic cancer has remained low, around 9-12 months.
• Unlike many other cancers, pancreatic cancer has shown limited response to conventional targeted agents and immunotherapy.
• The dense stroma surrounding pancreatic tumors contributes to its resistance to existing treatments.
• The KRAS gene is a critical protein that, when mutated, becomes constantly active, leading to uncontrolled cell growth.
• Daraxonrasib works by inhibiting this "ON" state of the mutated KRAS gene from within the cell, suppressing cancer proliferation.
• It is the first drug in its class to successfully inhibit RAS activity broadly, regardless of specific mutation subtypes.
• While effective, the drug has significant side effects, comparable to chemotherapy, including skin rash and fatigue.
• Currently, it is intended for patients with advanced pancreatic cancer who have already undergone chemotherapy and experienced disease progression.
• Future research is exploring its use in treatment-naive patients and its potential application in other cancers with RAS mutations, such as lung and colon cancers.
• The drug is not yet available in India, but its potential suggests it may be introduced soon.

Key Concepts Involved:

• Pancreatic Cancer: An aggressive malignancy originating in the pancreas, often characterized by late diagnosis and poor prognosis.
• KRAS Gene: A proto-oncogene frequently mutated in various cancers, including pancreatic cancer, leading to uncontrolled cell division and growth.
• Precision Oncology: A personalized approach to cancer treatment that tailors therapies based on the specific genetic and molecular characteristics of an individual's tumor.
• Stroma: The supportive connective tissue surrounding a tumor, which can create a physical and biological barrier, hindering drug delivery and treatment efficacy.